A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

rituximab 375 mg/m2 on days -11 and -4, The second dose of rituximab (day -4) is administered 7 days after the first dose (day -11), +/- 1 day. Rituximab may be administered by a local oncologist. If the participant has a CD20 negative tumor, rituximab can be omitted from the conditioning regimen.

bendamustine 160 mg/m2 intravenously on days -3 and -2

melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0.

reinfusion of autologous stem cells on day 0.